Search and Filter
Results per Page:
Fred Hutch researchers discover molecular switch that helps prostate cancer quickly change its biology to evade therapy
Drs. Andrew Hsieh and Rashmi Mishra identify a key step in the protein-making process that turns a treatable form of prostate cancer into a more lethal, drug-resistant subtype — and a way to switch it back
Dr. Andrew Hsieh named Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research
A new endowed chair created by Larry and Virginia Gordon helps accelerate discoveries for bladder and prostate cancer
Small cell lung cancer research gets a boost
Drs. David MacPherson and Gavin Ha receive $1.5M from Andy Hill CARE Fund to create much-needed liquid biopsy for SCLC
Let cancer eat cake
Fred Hutch study finds that feeding NRF2-mutated tumors too much of a nutrient they crave makes them vulnerable to slower growth and cell death
Two Fred Hutch postdocs receive prestigious Damon Runyon awards
The early-career scientists will study the biology of acute myeloid leukemia and how certain treatments can make immunocompromised cancer patients more vulnerable to lung infections
Fred Hutch researchers receive Prostate Cancer Foundation Young Investigator Awards
Three-year projects explore epigenetics to make new therapies or make existing therapies work better
Fred Hutch study dramatically expands therapeutic range of approved kinase drugs
Large-scale analysis reveals new uses for existing therapies across cancer types and non-cancer diseases
Fred Hutch brings together rare cancer community
Patients and caregivers share frustrations, practical realities of rare cancer life at TRACER program’s first education symposium
Fred Hutch collaboration reveals molecular vulnerability in rare childhood brain cancer
Researchers uncover a weak link in tumors driven by a notorious gene fusion that could be targeted with a drug
Giving CAR T cells a portable pit crew
Fred Hutch scientists dig deep into the biology of CAR T-cell exhaustion and examine experimental strategy to improve the immunotherapy for solid tumors
Fred Hutch researchers discover an unknown soldier in defense against viruses
A gene better known for its role in cancer progression also plays a surprising role in mounting an immune defense against Zika virus
Showcasing new strides in rare cancer research
Fred Hutch 4th Rare Cancers Symposium features local and national experts in critical research areas including immunotherapy, clinical trial design and biobanking
Brandeis University honors Fred Hutch molecular biologist
Dr. Steven Henikoff receives 55th Lewis S. Rosenstiel Award for Distinguished Work in Basic Medical Research
Dr. Yeon Soo Kim receives NIH Pathway to Independence Award
Hsieh Lab postdoctoral fellow studies how advanced prostate cancer evades therapy by altering the way RNA builds proteins
Fred Hutch study finds new life for ‘ineffective’ drugs
Innovative method using more authentic tumor samples reveals untapped potential for drugs written off by more conventional tests
Conducting RNA reconnaissance
Fred Hutch researchers invent a CRISPR screening method to understand RNA-binding proteins often mutated in cancer and other diseases
Virologist and HIV expert Dr. Michael Emerman retires
Emerman considers mentorship his most important duty in science
Kuni Foundation awards $7M to drive adult oncology research forward
Vancouver, Washington-based foundation supports innovative early-stage research on new potential therapies
Two Fred Hutch studies identify pancreatic cancer biomarker driving basal disease
Dr. Sita Kugel’s team recently published two papers identifying a key biological signature that not only provides clinics a faster, cheaper way to tell pancreatic cancer subtypes apart, but reveals a biological mechanism that could lead to new therapies
Fred Hutch study finds genetic driver of drug resistance in small cell lung cancer
Researchers use CRISPR-Cas9 gene-editing tool on tumor cells grown in mice to better model how tumors that initially respond to chemotherapy become resistant